ArticleJournal of Ayurveda and integrative medicine
Multitarget anticancer profiling of Withania somnifera - Dual herbal combination with P. emblica, B. monnieri, and O. basilicum through integrated In silico docking and In vitro Jurkat cell line analysis.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombinatorial Ayurvedic Rasayana extracts represent a rich source of bioactive compounds with anticancer potential. Withania somnifera (W) and its dual herbal Rasayana partners-Phyllanthus emblica (WP), Bacopa monnieri (WB), and Ocimum sanctum (WO)-are traditionally used to restore immune function, enhance resilience, and improve systemic health. Their multi-targeted phytoconstituents provide a promising approach for cancer therapy.
objectiveThis study aimed to identify bioactive compounds from W. somnifera and its dual Rasayana extracts, evaluate their in silico binding affinity with cancer-related targets, and assess their in vitro antiproliferative potential compared with cladribine. MATERIALS AND
methodsPhytocompounds were identified by GCMS and pharmacological activities were predicted using PASS-BAS. Molecular docking (Schrodinger- Glide) against 23 cancer-relevant proteins curated from TCGA and COSMIC datasets. Drug-likeness and ADME were evaluated with QikProp 3.0 and SwissADME. Molecular Dynamics (MD) simulations (100 ns, Desmond) were conducted for selected protein-ligand complexes to validate binding stability through RMSD, RMSF, SSE, and protein-ligand interaction analysis. Jurkat E6-1 leukemia cells were treated with W, WP3, WB2, and WO3 extracts for 24 h, and antiproliferative activity assessed via MTT assay.
resultsOf 62 screened phytocompounds, four key ligands -Campesterol (W), WP ligand, WB ligand, and Retinol (WO)-based on drug-likeness, pharmacokinetics, and compared with Cladribine. Docking revealed high affinities: WP3 with FAAH (-10), WB2 with PPARD (-9.08) and RBP4 (-9.5), WO3 with PPARA (-9.85) and RBP4 (-10.23), and W with CYP17A1 (-8.74). Enrichment analysis linked these targets to MAPK, JAK-STAT, and PPAR pathways. The MD results of both the complexes (5NUJ-445354 and 4D03-9592405) showed acceptable stability with dynamic adaptability, supporting the robustness of docking predictions. WP3 and WO3 had the highest antiproliferative activity (IC
conclusionThis first integrative in silico-invitro analysis of dual herbal Rasayana extracts reveals multi-target anticancer activity and validates the stability of the key protein-ligand interactions suggesting synergistic therapeutic potential of W. somnifera with P. emblica as promising lead formulations for further drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.